What drove the 0241.HK stock rally on 15 Jan 2026?

The stock jumped due to Beijing’s cloud integration push for healthtech and heavy buying. Alibaba Health’s exposure to pharmacy e‑commerce and internet hospital services made it a top mover in Hong Kong with volume at **1,001,184,882.00** shares.

How expensive is 0241.HK stock on valuation metrics?

Valuation is elevated: reported PE **59.85**, price-to-book **5.84**, and price-to-sales **2.69**. These multiples reflect growth expectations but imply limited margin for earnings disappointment.

What does Meyka AI forecast for 0241.HK stock?

Meyka AI's forecast model projects a 12‑month target of **HK$7.22** and a three‑year target of **HK$10.69**. These are model projections and not guarantees; today’s price of **HK$7.78** implies short-term downside but longer-term upside potential.

Is 0241.HK stock a buy after the surge?

Meyka AI assigns a Grade **B (HOLD)** with a score **68/100**. Given elevated multiples and policy upside, cautious investors may wait for consolidation or clearer earnings beats before increasing exposure.

HK Stocks

0241.HK Alibaba Health up 18.96% on 15 Jan 2026: heavy volume signals momentum

ByDanny Kontos January 15, 2026January 15, 2026

0241.HK stock climbed 18.96% to HK$7.78 on 15 Jan 2026 on unusually high turnover, closing the Hong Kong (HKSE) session strongly. Volume surged to 1,001,184,882.00 shares versus an average of 80,160,910.00, marking the stock as one of the Hong Kong market’s most active issues today. The move followed Beijing’s cloud integration push for healthtech and lifted sector peers, driving renewed investor focus on Alibaba Health Information Technology Limited (0241.HK). We examine price drivers, valuation, technical signals and Meyka AI’s model outlook for traders and longer-term investors.